Latest Options News

G50 Corp has completed the acquisition of 100% ownership of its Golconda Project in Arizona, following significant exploration successes that position the company for accelerated development and commercialisation.

Australian Mines Limited has raised $4 million through a strongly supported placement, enabling expanded drilling at its premium Flemington Scandium and Boa Vista Gold projects.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

St Barbara updates shareholders on its ongoing strategic review, highlighting stalled Atlantic separation talks and advancing Simberi sale discussions, while reaffirming commitment to a major expansion.

Delorean Corporation has released its audited 2025 Annual Report, revealing key adjustments from its preliminary results including lower revenue, increased tax expenses, and a significant reclassification of borrowings.

Quantum Graphite Ltd reported a significant revenue jump alongside a $4.9 million net loss for FY2025, as it pushes forward with its Uley 2 graphite project backed by major infrastructure and funding initiatives.

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

Ryzon Materials has expanded its engineering contract with Xinhai to fast track production at its Nachu Graphite Project, alongside a $500,000 capital raising from Xinhai. The deal involves a $3.5 million contract largely settled through shares and options, pending shareholder approval.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.

Riversgold has partnered with MEGA Resources to fully fund and operate mining at its Northern Zone Gold Project near Kalgoorlie, sharing profits equally and aiming to commence mining in early 2026.